U.S. Pharmaceuticals & Biotech Buy the Dip

Palvella Therapeutics

Market Cap: US$2.1b

A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.

Syndax Pharmaceuticals

Market Cap: US$1.9b

A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.

Damora Therapeutics

Market Cap: US$1.8b

A biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America.

Sarepta Therapeutics

Market Cap: US$1.7b

A commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.

COMPASS Pathways

Market Cap: US$1.6b

Operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.

Annexon

Market Cap: US$868.4m

A clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.

Rigel Pharmaceuticals

Market Cap: US$681.2m

A biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.

Immix Biopharma

Market Cap: US$626.5m

A clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.

4D Molecular Therapeutics

Market Cap: US$542.6m

A late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.

Prelude Therapeutics

Market Cap: US$389.8m

A clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.

Zentalis Pharmaceuticals

Market Cap: US$316.8m

A clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States.

MacroGenics

Market Cap: US$254.9m

A clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.

Adagene

Market Cap: US$222.7m

A clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China.

Karyopharm Therapeutics

Market Cap: US$160.7m

A commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.

PepGen

Market Cap: US$145.3m

A clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States.

CapForce

Market Cap: US$96.3m

A precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally.

Burning Rock Biotech

Market Cap: US$94.4m

Develops and sells cancer therapy selection tests in the People's Republic of China and the United States.

Kalaris Therapeutics

Market Cap: US$93.3m

A clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases.

Cypherpunk Technologies

Market Cap: US$70.4m

A privacy technology company, implements a digital asset strategy anchored by Zcash in the United States.

Clene

Market Cap: US$70.0m

A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.